NASDAQ: CLXTCalyxt Inc Stock
$0.34-0.02 (-5.56%)
Updated Mar 31, 2023
CLXT Price
$0.34
Fair Value Price
$0.43
Market Cap
$16.79M
52 Week Low
$0.13
52 Week High
$0.95
P/E
-0.92x
P/B
2.32x
P/S
43.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$157.00k
Earnings
-$16.89M
Gross Margin
100%
Operating Margin
-10,703.18%
Profit Margin
-10,758.6%
Debt to Equity
2.1
Operating Cash Flow
-$19M
Beta
1.17
Next Earnings
May 3, 2023
Ex-Dividend
N/A
Next Dividend
N/A
CLXT Overview
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLXT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLXT ($0.34) is undervalued by 21.07% relative to our estimate of its Fair Value price of $0.43 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CLXT ($0.34) is significantly undervalued by 21.07% relative to our estimate of its Fair Value price of $0.43 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CLXT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLXT due diligence checks available for Premium users.
Be the first to know about important CLXT news, forecast changes, insider trades & much more!
CLXT News
Valuation
CLXT fair value
Fair Value of CLXT stock based on Discounted Cash Flow (DCF)
Price
$0.34
Fair Value
$0.43
Undervalued by
21.07%
CLXT ($0.34) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLXT ($0.34) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLXT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLXT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.92x
Industry
20.18x
Market
22.13x
CLXT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.32x
Industry
2.41x
CLXT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLXT's financial health
Profit margin
Revenue
$42.0k
Net Income
-$2.8M
Profit Margin
-6,754.8%
CLXT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLXT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$22.4M
Liabilities
$15.2M
Debt to equity
2.1
CLXT's short-term assets ($4.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLXT's long-term liabilities ($13.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLXT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CLXT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.8M
Investing
-$11.0k
Financing
$95.0k
CLXT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLXT vs Food Stocks
Calyxt Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.